Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olomorasib Plus Pembrolizumab in Advanced NSCLC
NCT07639242Phase 2Suspended
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olomorasib in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival at 5 years. Started Oct 2026; status: suspended.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07639242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639242.